drugset / Trial / NCT00864838

Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

NCT00864838

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

Timeline

Start
2008-06
Primary completion
2009-02
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Acetazolamide Small molecule 250 mg Oral
Subject Brimonidine Small molecule